Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.
| Ticker |
BMY
|
| CIK | 0000014272 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions. EC approves BMS’ perioperative Opdivo and chemo for NSCLCThe approval is supported by the randomised Phase III CheckMate -77T trial outcomes. Judge shuts down drugmakers’ 340B rebate plans, for nowA district court ruled that the HHS does have the power to review drug manufacturers’ plans to pay hospitals rebates instead of upfront discounts on 340B medications. But it left the door open to the controversial reforms. Jim Cramer On Bristol-Myers Squibb: “Waiting For It To Bottom”Among the safety stocks discussed by Cramer during the episode on May 14, Bristol-Myers Squibb Company (NYSE:BMY) was first on his list as he said: “Let’s get started with the stocks that sold off hard today, because I think it’s really important, because you know most, if not all, of these companies. Why don’t we […] Bristol-Myers Squibb (NYSE:BMY) Gains EC Approval for Opdivo in Lung Cancer TreatmentBristol-Myers Squibb (NYSE:BMY) recently received European Commission approval for its Opdivo regimen in treating resectable non-small cell lung cancer, marking a significant regulatory milestone. Despite this positive development, the company's share price declined 2% over the last week. This price movement contrasts with the broader market trends, where major indexes like the S&P 500 and Dow Jones posted gains. While regulatory achievements of this nature would typically be favorable, the... |